Albelda, SM CAR T cell therapy for patients with solid tumors: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 2147–66 (2024). Article PubMed Google Scholar Fu, Q. et al. RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. ECclinicalMedicine 63102175 (2023). Article PubMed PubMed
Albelda, SM CAR T cell therapy for patients with solid tumors: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 2147–66 (2024).
Fu, Q. et al. RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. ECclinicalMedicine 63102175 (2023).
Shi, D. et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results from phase I trials. Clinical. Cancer Res. 263979–3989 (2020).
Du, G. et al. Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy. Forehead. Immunol. 151431211 (2024).
Giardino Torchia, M.L. et al. Rational design of chimeric antigen receptor T cells against glypican 3 uncouples toxicity from therapeutic efficacy. cytotherapy 24720–732 (2022).
Yang, J.D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16589–604 (2019).
Finn, R.S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. English. J.Med. 3821894-1905 (2020).
Abou-Alfa, GK et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1EVIDoa2100070 (2022).
Rizzo, A. and Brandi, G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer treatment. Community Res. 27100328 (2021).
Wang, Y. et al. The combination of atezolizumab plus bevacizumab makes unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation with acquired resistance. Exp. Hematol. Oncol. 1045 (2021).
Fowler, N.H. et al. Tisagenlecleucel in relapsed or refractory follicular lymphoma in adults: the phase 2 ELARA trial. Nat. Medicine. 28325–332 (2022).
Schuster, SJ et al. Tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma in adults. N. English. J.Med. 38045–56 (2019).
Shin, MH et al. Recent advances in CAR-based solid tumor immunotherapy. Cells 121606 (2023).
Steffin, D. et al. Interleukin-15-shielded CAR GPC3 T cells for patients with solid cancers. Nature 637940–946 (2025).
Qi, C. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastroesophageal junction cancer (CT041-ST-01): a randomized, open-label, phase 2 trial. Lancet 4052049-2060 (2025).
Ning, S. et al. Glypican-3, a novel prognostic marker of hepatocellular cancer, is associated with postoperative metastasis and recurrence in patients with hepatocellular cancer. Mol. Biol. Reps. 39351–357 (2012).
Guo, M., Zhang, H., Zheng, J. & Liu, Y. Glypican-3: a new target for the diagnosis and treatment of hepatocellular carcinoma. J. Cancer 112008-2021 (2020).
Giardino Torchia, ML & Moody, G. DIALing-up the preclinical characterization of genetically modified adoptive cellular immunotherapies. Forehead. Immunol. 141264882 (2023).
Tauriello, DVF, Sancho, E. & Batlle, E. Overcoming TGFβ-mediated immune evasion in cancer. Nat. Reverend Cancer 2225–44 (2022).
An, Y. et al. Transforming growth factor β and peripheral regulatory cells negatively correlate with overall survival of hepatocellular carcinoma. World J. Gastroenterol. 242733–2740 (2018).
Shirai, Y. et al. Plasma transforming growth factor-β 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 732275–2279 (1994).
Narayan, V. et al. TGFβ-insensitive armored CAR T cells targeting PSMA in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Medicine. 28724–734 (2022).
Park, B.V. et al. TGFβ1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer. Discovery of cancer. 61366-1381 (2016).
Abou-Alfa, GK et al. Cabozantinib in patients with advanced and progressive hepatocellular carcinoma. N. English. J.Med. 37954–63 (2018).
Bruix, J. et al. Regorafenib for Patients With Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Lancet 38956–66 (2017).
Zhu, A.X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein concentrations (REACH-2): a randomized, double-blind, placebo-controlled phase 3 trial. Oncol Lancet. 20282–296 (2019).
Kudo, M. et al. Lenvatinib versus sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet 3911163-1173 (2018).
Llovet, JM et al. Sorafenib in advanced hepatocellular carcinoma. N. English. J.Med. 359378–390 (2008).
Sol, L. et al. Elimination antigen-induced blocking effect on CAR-T cells targeting glypican-3 in hepatocellular carcinoma. J. Immunotro. Cancer. 9e001875 (2021).
Ren, Z. et al. Sintilimab plus bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a phase 2-3, randomized, open-label study. Lancet 22977–990 (2021).
For more tech updates, stay tuned to our blog.
